Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014 (2014), Article ID 680502, 9 pages
http://dx.doi.org/10.1155/2014/680502
Research Article

Clinical and Renal Biopsy Findings Predicting Outcome in Renal Thrombotic Microangiopathy: A Large Cohort Study from a Single Institute in China

1Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing 100034, China
2Department of Nephrology, The First Affiliated Hospital of Chinese PLA General Hospital, 51 Fucheng Road, Beijing 100048, China
3Peking-Tsinghua Center for Life Sciences, Beijing 100871, China

Received 11 April 2014; Revised 6 July 2014; Accepted 20 July 2014; Published 11 August 2014

Academic Editor: Friedrich Thaiss

Copyright © 2014 Xiao-Juan YU et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Barbour, S. Johnson, S. Cohney, and P. Hughes, “Thrombotic microangiopathy and associated renal disorders,” Nephrology Dialysis Transplantation, vol. 27, no. 7, pp. 2673–2685, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. L. Fernández, J. C. Rojo, G. Í. Martín, R. M. Alonso, and J. V. Martín, “Hemolytic uremic syndrome: long term renal injury,” Anales de Pediatria, vol. 72, no. 5, pp. 309–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. X. Garg, R. S. Suri, N. Barrowman et al., “Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression,” The Journal of the American Medical Association, vol. 290, no. 10, pp. 1360–1370, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Morel-Maroger, A. Kanfer, K. Solez, J. D. Sraer, and G. Richet, “Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic-uremic syndrome): clinicopathologic study in 20 adults,” Kidney International, vol. 15, no. 5, pp. 548–558, 1979. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Benhamou, C. Assié, P. Y. Boelle et al., “Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience,” Haematologica, vol. 97, no. 8, pp. 1181–1186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Caprioli, M. Noris, S. Brioschi et al., “Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome,” Blood, vol. 108, no. 4, pp. 1267–1279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Noris, J. Caprioli, E. Bresin et al., “Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 10, pp. 1844–1859, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Fremeaux-Bacchi, F. Fakhouri, A. Garnier et al., “Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide french series comparing children and adults,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 4, pp. 554–562, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. L. H. Wu, F. Yu, Y. Tan et al., “Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions,” Kidney International, vol. 83, no. 4, pp. 715–723, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Karpman and R. Tati, “Complement activation in thrombotic microangiopathy,” Hamostaseologie, vol. 33, no. 2, pp. 96–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Chang, “Thrombotic microangiopathy and the kidney: a nephrologist’s perspective,” Diagnostic Histopathology, vol. 19, no. 5, pp. 158–165, 2013. View at Google Scholar
  12. B. F. Wyllie, A. X. Garg, J. Macnab, G. A. Rock, and W. F. Clark, “Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange,” British Journal of Haematology, vol. 132, no. 2, pp. 204–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Rose, J. M. Rowe, and A. Eldor, “The changing course of thrombotic thrombocytopenic purpura and modern therapy,” Blood Reviews, vol. 7, no. 2, pp. 94–103, 1993. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Legendre, C. Licht, P. Muus et al., “Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome,” The New England Journal of Medicine, vol. 368, no. 23, pp. 2169–2181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Fakhouri, C. Vercel, and V. Frémeaux-Bacchi, “Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 12, pp. 2100–2106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Yu, Y. Tan, and M. Zhao, “Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome,” Nephrology Dialysis Transplantation, vol. 25, no. 1, pp. 145–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. F. M. Wang, F. Yu, Y. Tan, D. Song, and M. Zhao, “Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis,” Rheumatology, vol. 51, no. 12, Article ID kes218, pp. 2269–2277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Dragon-Durey, C. Loirat, S. Cloarec et al., “Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome,” Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 555–563, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Cohen, M. Koopmans, H. I. C. Kremer et al., “Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis,” Arthritis and Rheumatism, vol. 58, no. 8, pp. 2460–2469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. N. George, “How I treat patients with thrombotic thrombocytopenic purpura: 2010,” Blood, vol. 116, no. 20, pp. 4060–4069, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Fujimura and M. Matsumoto, “Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998–2008,” Internal Medicine, vol. 49, no. 1, pp. 7–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Fan, Y. Yoshida, S. Honda et al., “Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome,” Molecular Immunology, vol. 54, no. 2, pp. 238–246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. H. M. Tsai, “Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome,” The American Journal of Medicine, vol. 126, no. 3, pp. 200–209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J. N. George, S. K. Vesely, D. R. Terrell et al., “The oklahoma thrombotic thrombo—cytopenic purpura-haemolytic uraemic syndrome registry a model for clinical research, education and patient care,” Hamostaseologie, vol. 33, no. 2, pp. 105–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Levandovsky, D. Harvey, P. Lara, and T. Wun, “Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients,” Journal of Hematology and Oncology, vol. 1, no. 1, article 23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Scully, B. J. Hunt, S. Benjamin et al., “Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies,” The British Journal of Haematology, vol. 158, no. 3, pp. 323–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. C. M. Taylor, S. MacHin, S. J. Wigmore, and T. H. J. Goodship, “Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom,” The British Journal of Haematology, vol. 148, no. 1, pp. 37–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. U. Abildgaard and K. Heimdal, “Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 166, no. 2, pp. 117–123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. S. E. Maynard, J. Y. Min, J. Merchan et al., “Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 649–658, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. O. Pourrat, R. Coudroy, and F. Pierre, “ADAMTS13 deficiency in severe postpartum HELLP syndrome,” British Journal of Haematology, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Ardissino, M. W. Ossola, G. M. Baffero, A. Rigotti, and M. Cugno, “Eculizumab for atypical hemolytic uremic syndrome in pregnancy,” Obstetrics and Gynecology, vol. 122, no. 2, part 2, pp. 487–489, 2013. View at Publisher · View at Google Scholar · View at Scopus